Literature DB >> 19415685

FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer.

Maija P Valta1, Johanna Tuomela, Heikki Vuorikoski, Niina Loponen, Riina-Minna Väänänen, Kim Pettersson, H Kalervo Väänänen, Pirkko L Härkönen.   

Abstract

Fibroblast growth factor 8 (FGF-8) is expressed at an increased level in a high proportion of prostate cancers and it is associated with a poor prognosis of the disease. Our aim was to study the effects of FGF-8b on proliferation of PC-3 prostate cancer cells and growth of PC-3 tumors, and to identify FGF-8b-associated molecular targets. Expression of ectopic FGF-8b in PC-3 cells caused a 1.5-fold increase in cell proliferation in vitro and a four- to fivefold increase in the size of subcutaneous and orthotopic prostate tumors in nude mice. Tumors expressing FGF-8b showed a characteristic morphology with a very rich network of capillaries. This was associated with increased spread of the cancer cells to the lungs as measured by RT-qPCR of FGF-8b mRNA. Microarray analyses revealed significantly altered, up- and downregulated, genes in PC-3 cell cultures (169 genes) and in orthotopic PC-3 tumors (61 genes). IPA network analysis of the upregulated genes showed the strongest association with development, cell proliferation (CRIP1, SHC1), angiogenesis (CCL2, DDAH2), bone metastasis (SPP1), cell-to-cell signaling and energy production, and the downregulated genes associated with differentiation (DKK-1, VDR) and cell death (CYCS). The changes in gene expression were confirmed by RT-qPCR. In conclusion, our results demonstrate that FGF-8b increases the growth and angiogenesis of orthotopic prostate tumors. The associated gene expression signature suggests potential mediators for FGF-8b actions on prostate cancer progression and metastasis. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415685     DOI: 10.1002/jcb.22175

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  12 in total

1.  Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice.

Authors:  Teresa D Elo; Eeva M Valve; Jani A Seppänen; Heikki J Vuorikoski; Sari I Mäkelä; Matti Poutanen; Paula M Kujala; Pirkko L Härkönen
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

Review 2.  Polyunsaturated fatty acid metabolism in prostate cancer.

Authors:  Isabelle M Berquin; Iris J Edwards; Steven J Kridel; Yong Q Chen
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

Review 3.  CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-14       Impact factor: 7.638

4.  Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts.

Authors:  Johanna Tuomela; Tove J Grönroos; Maija P Valta; Jouko Sandholm; Aleksi Schrey; Jani Seppänen; Päivi Marjamäki; Sarita Forsback; Ilpo Kinnunen; Olof Solin; Heikki Minn; Pirkko L Härkönen
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

5.  Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens.

Authors:  Riina-Minna Väänänen; Hans Lilja; Angel Cronin; Leni Kauko; Maria Rissanen; Otto Kauko; Henna Kekki; Siina Vidbäck; Martti Nurmi; Kalle Alanen; Kim Pettersson
Journal:  Clin Biochem       Date:  2013-02-04       Impact factor: 3.281

6.  Growth factors involve in cellular proliferation, differentiation and migration during prostate cancer metastasis.

Authors:  Ilaha Isali; Mohammed Adel Ali Al-Sadawi; Arshna Qureshi; Ahmad O Khalifa; Mukesh K Agrawal; Sanjeev Shukla
Journal:  Int J Cell Biol Physiol       Date:  2019-10-07

7.  Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP).

Authors:  Raquel Frenedoso da Silva; Ellen Nogueira-Pangrazi; Larissa Akemi Kido; Fabio Montico; Sarah Arana; Dileep Kumar; Komal Raina; Rajesh Agarwal; Valéria Helena Alves Cagnon
Journal:  J Biomed Sci       Date:  2017-05-12       Impact factor: 8.410

8.  Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.

Authors:  Lori E Lowes; David Goodale; Ying Xia; Carl Postenka; Matthew M Piaseczny; Freeman Paczkowski; Alison L Allan
Journal:  Oncotarget       Date:  2016-11-15

9.  Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors.

Authors:  Johanna Tuomela; Maija Valta; Jani Seppänen; Kati Tarkkonen; H Kalervo Väänänen; Pirkko Härkönen
Journal:  BMC Cancer       Date:  2009-10-12       Impact factor: 4.430

10.  Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators.

Authors:  Raquel Frenedoso da Silva; Deepanshi Dhar; Komal Raina; Dileep Kumar; Rama Kant; Valeria Helena Alves Cagnon; Chapla Agarwal; Rajesh Agarwal
Journal:  Sci Rep       Date:  2018-06-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.